Heritability of hematologic malignancies: from pedigrees to genomics.
Many hematologic malignancies have an underlying heritable component. Although not as well characterized as the acquired genetic abnormalities that define important prognostic and therapeutic subgroups of myeloid and lymphoid neoplasms, investigations are beginning to unravel the role of germline genetic variation in the predisposition to hematologic malignancies. Information gained from the study of striking family pedigrees, epidemiologic data, and candidate genes are now being combined with unbiased genome-wide investigations to outline the network of genetic abnormalities that contribute to hematologic malignancy risk. This article reviews the current understanding of the heritability of hematologic malignancies in the genomics era.
Churpek
Jane E
JE
Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL 60637, USA.
Onel
Kenan
K
D005820:Genetic Testing; D023281:Genomics / Q000379:methods*; D019337:Hematologic Neoplasms / Q000235:genetics*; D006801:Humans; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics*; D010375:Pedigree